U.S. drug manufacturers with products in late-stage clinical trials and on the path to FDA approval may be overlooking an important consideration: preparing for serialization. Starting this November, ...

Recent research shows that the pharmaceutical industry is intensifying efforts to combat counterfeit drugs, which account for up to 30% of medicines sold globally. In a major step toward securing ...

There’s a long list of deadlines associated with the Food and Drug Administration’s (FDA) Drug Supply Chain Security Act (DSCSA), all of which relate to the exchange of transaction information, ...

The major markets for pharmaceuticals have been forever transformed with the arrival of mandated serialization. With both the United States Drug Supply Chain Security Act (DSCSA) and European Union ...

Pharmaceutical counterfeiting is on the rise – and a growing health and safety issue with deep consequences for consumers and manufacturers alike. A number of factors contribute to counterfeiting, ...